| Full Name | Ribosomal Protein L39 |
|---|
| Chromosomal Location | Xq24 |
|---|
| NCBI Gene ID | [6170](https://www.ncbi.nlm.nih.gov/gene/6170) |
|---|
| Ensembl ID | [ENSG00000198918](https://www.ensembl.org/Homo_sapiens/ENSG00000198918) |
|---|
| UniProt ID | [P62875](https://www.uniprot.org/uniprot/P62875) |
|---|
| Protein Length | 51 amino acids |
|---|
| Molecular Weight | ~6 kDa |
|---|
| Associated Diseases | [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Breast Cancer](/diseases/breast-cancer), [Pancreatic Cancer](/diseases/pancreatic-cancer), [Ovarian Cancer](/diseases/ovarian-cancer) |
|---|
| Function | Component of 60S ribosomal subunit, protein synthesis |
|---|
RPL39 is a ribosomal protein that functions as a core component of the 60S large ribosomal subunit. The protein is encoded by the RPL39 gene located on chromosome Xq24 in humans. As part of the ribosome machinery, RPL39 plays an essential role in protein synthesis, which is fundamental to all cellular processes. NCBI Gene: RPL39
Ribosomes, the molecular machines responsible for protein synthesis, consist of two subunits: a small 40S subunit that mediates mRNA binding and decoding, and a large 60S subunit that catalyzes peptide bond formation. The 60S subunit contains approximately 47 proteins, including RPL39, along with three rRNA molecules (28S, 5.8S, and 5S).
¶ Gene Structure and Evolution
The RPL39 gene spans approximately 4.5 kb of genomic DNA and contains 4 exons. It is located on the long arm of chromosome X (Xq24), a region that has undergone significant evolutionary conservation. The gene is housekept in its expression pattern, being ubiquitously expressed across all human tissues at varying levels.
RPL39 is highly conserved across eukaryotes, with homologs present in organisms ranging from yeast to humans. The protein belongs to the L39E family of ribosomal proteins, characterized by a conserved C-terminal domain that interacts with the rRNA of the 60S subunit. UniProt P62875
Humans possess a paralogous gene, RPL39L (RPL39-like), located on chromosome 4. RPL39L shares 89% sequence identity with RPL39 and is primarily expressed in testis, kidney, and neural tissues. The functional significance of RPL39L includes:
- Compensatory function: RPL39L can partially compensate for RPL39 deficiency in certain tissues
- Tissue-specific roles: Higher expression in neuronal cells suggests specialized functions in neural development
- Cancer association: Altered RPL39L expression has been reported in several cancer types
¶ Protein Structure and Function
RPL39 is a small protein of approximately 51 amino acids with a molecular weight of approximately 6 kDa. Despite its small size, it plays a crucial role in ribosome structure and function. UniProt P62875
The protein adopts a compact, highly basic structure that facilitates binding to the 28S rRNA of the 60S subunit. Key structural features include:
- N-terminal domain: Involved in protein-protein interactions with other ribosomal proteins
- rRNA binding interface: Conserved positively charged residues for rRNA interaction
- C-terminal tail: Extends into the peptidyl transferase center
RPL39 contributes to several critical aspects of ribosomal function:
- Ribosome assembly: Essential for proper 60S subunit biogenesis
- tRNA positioning: Participates in positioning the 3'-end of tRNA in the P-site
- Peptide bond formation: Contributes to the peptidyl transferase center's architecture
- Translation fidelity: Involved in monitoring codon-anticodon interactions
RPL39 is ubiquitously expressed, with highest levels in tissues with high protein synthetic demand:
| Tissue |
Expression Level |
Notes |
| Bone marrow |
High |
Hematopoietic cells |
| Liver |
High |
Metabolic activity |
| Skeletal muscle |
High |
Protein synthesis |
| Brain |
Moderate |
Neuronal activity |
| Testis |
Moderate |
Spermatogenesis |
| Kidney |
Moderate |
Tubular transport |
RPL39 is primarily localized to the cytoplasm, where ribosomes are predominantly found. However, a small fraction is associated with:
- Mitochondrial ribosomes: Supporting mitochondrial translation
- Endoplasmic reticulum: Attached ribosomes for secretory protein synthesis
- Synaptic ribosomes: Local protein synthesis in neurons
RPL39 mutations were first identified as causative in Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome characterized by:
- Pure red cell aplasia: Failure of red blood cell production
- Congenital anomalies: Craniofacial abnormalities, thumb anomalies
- Cancer predisposition: Increased risk of myelodysplastic syndrome and acute myeloid leukemia
- Growth retardation: Failure to thrive in infancy
The discovery of RPL39 mutations in DBA expanded the spectrum of ribosomal protein genes mutated in this ribosomopathy. Unlike mutations in other DBA genes (RPS19, RPS24, RPS26), RPL39 mutations are X-linked due to its chromosomal location.
RPL39 mutations in DBA cause disease through several mechanisms:
- Ribosome biogenesis defects: Impaired 60S subunit assembly
- p53 activation: Ribosomal stress activates p53-dependent cell cycle arrest
- Selective translation deficits: Impaired translation of specific mRNAs
- Hematopoietic stem cell failure: Defective erythropoiesis due to sensitive translational requirements
Altered RPL39 expression has been reported in multiple cancer types:
RPL39 overexpression has been documented in breast cancer, associated with:
- Tumor progression: Higher RPL39 correlates with advanced stage
- Metastasis: Linked to increased metastatic potential
- Poor prognosis: Associated with reduced overall survival
- Mechanisms: Enhanced translation of oncogenic mRNAs
In pancreatic ductal adenocarcinoma, RPL39:
- Promotes growth: Knockdown inhibits tumor cell proliferation
- Chemoresistance: Associated with resistance to gemcitabine
- Metabolism: Supports increased metabolic demands
RPL39 has been shown to:
- Drive progression: Promotes ovarian cancer cell migration and invasion
- Interact with AGK: Partners with acylglycerol kinase to enhance tumor initiation
- Metastatic potential: Associated with peritoneal dissemination
While RPL39 is not directly implicated in neurodegenerative diseases, ribosomal protein dysfunction is increasingly recognized in neurodegeneration:
Studies have identified alterations in ribosomal proteins in AD brain tissue:
- Translation deficits: Impaired protein synthesis in neurons
- Ribosome quality: Reduced ribosome numbers and function
- Synaptic translation: Disrupted local translation at synapses
- p53 activation: Ribosomal stress may contribute to neuronal loss
Ribosomal dysfunction has been implicated in PD:
- Mitochondrial translation: Defects in mitochondrial ribosome function
- Alpha-synuclein translation: Altered translation of PD-related proteins
- Neuronal vulnerability: Specific sensitivity of dopaminergic neurons
Ribosomal protein alterations have been observed in PSP brain tissue:
- Translation impairment: Global reduction in protein synthesis
- Tau translation: Potential dysregulation of tau protein synthesis
- Neuronal loss: Contributes to characteristic neurodegeneration
¶ Role in Neural Development and Function
During neural development, RPL39 supports:
- Neurogenesis: Protein synthesis requirements for neuron production
- Axonal growth: Local translation in growing axons
- Synaptogenesis: Synthesis of synaptic proteins
- Myelination: Support of oligodendrocyte protein synthesis
At synapses, RPL39 contributes to local protein synthesis essential for:
- Synaptic plasticity: Activity-dependent protein synthesis
- Long-term potentiation: New protein synthesis for LTP maintenance
- Memory consolidation: Local translation in dendritic spines
- Synaptic remodeling: Protein turnover at synaptic terminals
RPL39 participates in mitochondrial translation:
- Mitochondrial ribosomes: Component of the mitochondrial translation machinery
- ATP production: Supports synthesis of mitochondrial-encoded proteins
- Cellular energy: Maintains cellular energy homeostasis
- Oxidative stress: Mitochondrial dysfunction affects neuronal health
¶ Ribosomal Stress and p53
The connection between ribosomal protein deficiency and p53 activation provides a unified mechanism for disease pathogenesis:
- Ribosomal stress: Deficient ribosomal proteins trigger stress response
- MDM2 inhibition: Free ribosomal proteins bind MDM2
- p53 stabilization: Accumulation of active p53
- Cell cycle arrest: p53-dependent growth arrest or apoptosis
This pathway explains the bone marrow failure in DBA and may contribute to neuronal loss in ribosomal dysfunction.
Ribosomal protein mutations impair cellular proteostasis:
- Translation capacity: Reduced protein synthesis capability
- mRNA specialization: Impaired translation of specific transcripts
- ER stress: Unfolded protein response activation
- Autophagy: Altered protein clearance mechanisms
Ribosomal proteins are crucial for stem cell function:
- Hematopoietic stem cells: RPL39 deficiency impairs HSC function
- Neural stem cells: Potential role in neurogenesis
- Cancer stem cells: Altered ribosome function in CSCs
- Tissue regeneration: Impairs regenerative capacity
Knockout and transgenic mouse models have been developed to study RPL39 function:
- RPL39 knockout: Embryonic lethal, demonstrates essential function
- Conditional knockout: Tissue-specific deletion reveals tissue requirements
- Transgenic overexpression: Models RPL39 overexpression in cancer
Zebrafish provide valuable models for studying RPL39 in development:
- Morpholino knockdown: Reveals developmental defects
- CRISPR models: Precise gene editing for disease modeling
- In vivo imaging: Visualize ribosome function in real-time
Current and potential therapeutic approaches include:
- Corticosteroids: First-line treatment to stimulate erythropoiesis
- Supportive care: Transfusions for anemia management
- Curative options: Hematopoietic stem cell transplantation
- Gene therapy: Future potential for genetic correction
Targeting RPL39 in cancer presents opportunities:
- Translation inhibitors: Drugs targeting protein synthesis
- Ribosome biogenesis: Inhibitors of ribosome assembly
- Synthetic lethality: Exploiting RPL39 dependence in tumors
- Combination therapy: With standard chemotherapeutics
Ribosomal function represents a therapeutic target:
- Translation enhancement: Agents to boost protein synthesis
- Ribosome stabilizers: Protect ribosomal function
- mTOR modulators: Upstream translation pathway targeting
- Antioxidants: Address secondary oxidative stress
¶ Genetics and Polymorphisms
The RPL39 gene exhibits various polymorphisms:
- Missense variants: May affect protein function
- Copy number variations: Altered gene dosage in disease
- Splice variants: May produce altered isoforms
In cancer, RPL39 can acquire somatic mutations:
- Point mutations: Observed in various cancer types
- Gene amplification: Common in aggressive tumors
- Expression alterations: Frequently upregulated
RPL39 testing is relevant for:
- DBA diagnosis: Genetic testing for suspected DBA
- Differential diagnosis: Distinguishing DBA from other anemias
- Family screening: Identifying affected relatives
- Prenatal testing: For families with known mutations
RPL39 expression has prognostic implications:
- Cancer prognosis: Higher expression often indicates worse outcome
- DBA severity: May predict treatment response
- Therapeutic targeting: Informs treatment selection
¶ Outstanding Questions
Key research areas include:
- Mechanism of DBA: How RPL39 mutations cause specific erythroid failure
- Cancer dependency: Why tumors become dependent on RPL39
- Neural function: Specific role in neurons vs. other cell types
- Therapeutic targeting: Developing selective inhibitors
- Single-cell analysis: Understanding cell-type specific effects
- Structural biology: High-resolution ribosome structures
- Translation profiling: Genome-wide translation analysis
- Therapeutic development: Small molecule and gene therapies